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fusion-treated patient but the average epoetin-and-
transfusion-free costs were very similar in the two groups.
The costs varied highly between centres, but a high EAI
independently decreased the without-epoetin-costs by
15%. CONCLUSIONS: An appropriate and homoge-
neous use of epoetin might reduce the costs of cancer
treatment.
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The recent introduction on the French market of 
HerceptinTM, an innovative drug associated to a high
acquisition cost, justiﬁes its economic assessment.
OBJECTIVE: The study aim was to compare 8 chemo-
therapies as ﬁrst-line treatment in MBC (doxorubicin 
(D) + cyclophosphamide (C); 2 combinations of 5-
Fluorouracile (F), Epirubicin (E) and C i.e. FEC50 and
FEC100; D + paclitaxel (P); D + docetaxel (T); E + P; 
E + T; H + P. METHODS: The study methodology,
according to a French payer perspective, is a cost-
effectiveness analysis based on a decision tree model.
Assessment considers the period from the diagnosis of
metastasis until the end therapy or death. The clinical
data are obtained from recently published phase III ran-
domised trials. Effectiveness was assessed through time to
progression criteria. Chemotherapy procedures, incidence
of adverse events, patient transport and nurse care follow
up were collected. Hospital costs were estimated through
the National Costs References per DRG. Medication
costs were estimated from standard dosages. General
Nomenclature of Practitioner Acts (NGAP) was used to
valuate ambulatory follow-up care. A sensibility analysis
was led on efﬁcacy criteria and main drivers cost.
RESULTS: The mean cost by week without progression
is €550 for H + P, €424 for E + T, €417 for E + P, €418
for D + T, €438 for D + P, €374 for FEC50, €324 for
FEC100 and €365 for D + C. The most effective combi-
nation appears to be E + T, as and the ﬁnancial sacriﬁce
associated with an additional one week without progres-
sion, as compared to FEC100 for instance, is €895.
Anthracyclins (D or E) + taxans (P or T) combinations
show a complete dominance when compared to the H +
T strategy, but the latter is only offered to the subpopu-
lation of patients showing the receptor over-expression, a
potential negative predictor for response to chemo-
therapy. CONCLUSIONS: Although this type of analysis
favours the use of anthracyclins + taxans combinations in
ﬁrst-line treatment of MBC, our hypothesis has to be con-
ﬁrmed by clinical pharmaco-economical trials.
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OBJECTIVES: Gemcitabine/cisplatin (GC) is one of
many novel chemotherapy regimens available for the
treatment of non-small cell lung cancer. This study con-
ducted two clinical trial-based economic evaluations 
comparing GC with other novel agent regimens in ﬁve
European countries: France, Germany, Italy, Spain, and
the UK. METHODS: The economic evaluations were
conducted using evidence from two randomised, con-
trolled trials of GC and the other novel regimens. The ﬁrst
analysis was based upon the trial published by Comella
et al. (2000) and compared GC with vinorelbine/cisplatin
(VC). The second analysis was based upon the trial pub-
lished by Schiller et al. (2000) and compared GC with
paclitaxel/cisplatin (PCI), paclitaxel/carboplatin (PCA)
and docetaxel/cisplatin (DC). In these trials, pivotal
health outcomes including overall and progression-free
survival were similar between GC and the other regimens
meaning cost-minimisation analysis was employed.
RESULTS: The analysis based on Comella et al. (2000)
found that GC was associated with lower total treatment
costs than VC in all ﬁve countries. The overall cost
savings associated with GC ranged from €802 in Spain to
£1,262 in the UK. The second analysis found that GC had
lower total treatment costs than both of the paclitaxel
regimens in all ﬁve countries. The overall cost savings 
for GC were greatest when compared against PCA and
ranged from €2,153 in Italy to €4,846 in France. GC was
associated with a small incremental cost compared to DC
in Germany (€95 per patient) and was cost saving in the
other four countries. CONCLUSIONS: GC was associ-
ated with lower total treatment costs than VC, PCI and
PCA from the perspective of the national health services
of ﬁve European countries. Given similar efﬁcacy ﬁndings
in these studies, a claim for cost-effectiveness of GC in
the treatment of advanced NSCLC is supported.
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OBJECTIVE: A number of new agents have become
available in the past decade for the treatment of non-
542 Abstracts
small-cell lung cancer (NSCLC). This study compares 
the cost savings associated with gemcitabine/cisplatin
(Gem/Cis) vs. other chemotherapy doublets under the
assumption of equal efﬁcacy. METHODS: The two ret-
rospective economic evaluations are based on Comella 
et al. (2000) and Schiller et al. (2002). Both studies
compare Gem/Cis with other novel regimens using evi-
dence from relevant prospective randomised, controlled
trials. Comella compares Gem/Cis with vinorelbine/
cisplatin (Vin/Cis). Schiller compares Gem/Cis with 
paclitaxel/cisplatin (Pac/Cis), paclitaxel/carboplatin (Pac/
Carbo) and docetaxel/cisplatin (Doc/Cis). UK costs were
drawn from appropriate UK reference cost schedules.
RESULTS: The economic evaluation based on the
Comella clinical trial indicated an average total cost
(ATC) for Gem/Cis of £4,998 which was £1,262 lower
than the ATC for Vin/Cis. Given the proven equal efﬁ-
cacy in treatment and higher levels of toxicity associated
with Vin/Cis, the analysis supports a cost-effectiveness
argument for use of Gem/Cis in the treatment of advanced
NSCLC. The economic evaluation based on the Schiller
et al. (2002) clinical trial indicated an ATC for Gem/Cis
of £6,144. This was lower than those treated with
Pac/Cis, Pac/Carbo and Doc/Cis with average savings of
£933, £2344 and £174 per patient, respectively. Gem/Cis
was still found to have the lowest total treatment costs
when subjected to univariate sensitivity analysis. CON-
CLUSIONS: For decision makers with a limited budget
the use of Gem/Cis is economically efﬁcient and offers to
maximise the number of patients that can be treated.
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OBJECTIVE: To assess the impact of anemia on medical
resource utilization in cancer patients undergoing
chemotherapy. METHOD: Medical charts of 116 cancer
patients (various tumor types) from 33 community oncol-
ogy practices across the United States, treated with
chemotherapy in 2000–01 and not treated with erythro-
poietic therapy, were evaluated. Anemia was deﬁned as
hemoglobin (Hb) of <12g/dL at baseline or at any point
of time during 28 weeks following chemotherapy initia-
tion. Medical resource utilization data on two major cost
drivers, emergency room (ER) visits and hospitalizations,
were compared for the anemic and non-anemic groups.
RESULTS: Fifty-eight (50%) patients were anemic. Of
the anemic patients, 26 (45%) had mild anemia (Hb
10.0–11.9g/dL) and 4 (7.5%) had moderate anemia (Hb
8.0–9.9g/dL) at baseline. The remaining 28 (48%)
patients became anemic during chemotherapy. There
were no signiﬁcant differences between the anemic and
non-anemic groups relative to co-morbidities, tumor type,
cancer stage, radiotherapy, and prior chemotherapy.
There was numerically higher amount of medical resource
utilization in anemic group. For moderate to severe
anemic sub-group, there was statistically signiﬁcant
(despite small patient numbers) higher utilization than in
non-anemic group: mean hospital admissions 0.58 vs.
0.19, p = 0.040; mean number of hospital admissions ≥5
days 0.25 vs. 0.07, p = 0.58; and mean ER visits 0.47 vs.
0.02, p = 0.022. CONCLUSION: Our study demon-
strated higher medical resource utilization associated with
anemia in chemotherapy-treated cancer patients. More
severe anemia may result in even higher utilization.
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OBJECTIVES: Non-small cell lung cancer (NSCLC) is a
leading cause of morbidity and mortality throughout
Europe. Clinical evidence in favour of gemcitabine/
platinum combination therapy as ﬁrst-line treatment in
advanced NSCLC has already been accepted. The present
study reports the methods and results of an analysis com-
paring the chemotherapy acquisition and administra-
tion costs of a 28-day gemcitabine/cisplatin regimen
(GEM/CIS) with a 28-day gemcitabine/carboplatin
regimen (GEM/CAR). METHODS: The analysis involved
quantiﬁcation and costing of medical resource utilisation
arising solely from planned differences in the treatment
regimens. Clinical outcomes achieved by the two regi-
mens were assumed to be equivalent. A simple micro-
costing of the costs associated with chemotherapy
administration incorporated a ﬁxed cost per administra-
tion plus a variable cost depending on the duration of the
intravenous infusion of the therapy being administered.
Threshold analysis derived the opportunity cost of patient
time spent in the chemotherapy unit at which GEM/
CAR becomes the cost-minimising treatment regimen.
RESULTS: Patients treated with GEM/CIS had a total
cost of €5,884 in France and £5,474 in the UK. The costs
of GEM/CAR were €6,607 and £5,599 in France and the
UK respectively. In both countries chemotherapy acquisi-
tion costs were higher, and administration costs lower for
patients treated with GEM/CAR. GEM/CAR became the
cost-minimising treatment when the opportunity cost of
time spent in the chemotherapy unit was approximately
€38.63 per hour in France or £15.83 in the UK. CON-
CLUSIONS: Drug administration costs of carboplatin
compared to cisplatin do not offset the additional
chemotherapy costs. However, ﬁnancial considerations
may not be paramount in the decision to treat patients
with GEM/CAR as opposed to GEM/CIS. Patient and
physician preference for a more convenient mode of
administration are clearly important factors.
